Overcoming Barriers in Drug Metabolism: Reaction Phenotyping Methods for Low Turnover Compound

Low metabolic turnover can make evaluating drug interactions challenging, including quantitating relative contribution of CYP isoforms involved in drug metabolism and hepatic clearance. Conventional 2D cell cultures simply cannot provide sufficient long-term viability and functionality for in vitro evaluation. In this webinar, we will discuss an inhibition method for reaction phenotyping by applying siRNA gene knockdown to inhibit enzyme activity for over two weeks in HEPATOPAC®, including a comparison of siRNA knockdown vs. chemical inhibitors to accurately determine the fraction metabolized for specific isoforms as well as comparing off-target effects. Download the slides: https://info.bioivt.com/bioivt-webina... Additional resources on this topic: https://bioivt.com/resources/educatio... Questions, comments and requests: https://bioivt.com/about/contact-us Access BioIVT's products and services: https://bioivt.com Other previously aired webinars: https://bioivt.com/educational-conten...) Upcoming webinar notifications: https://bioivt.com/resources/newslett... About the presenter: Jeannemarie Gaffney is the Senior Manager of Manufacturing and Process Development at BioIVT. Ms. Gaffney’s research efforts have focused on the development of tissue engineered products and cell based in vitro models with a focus on primary mammalian cell culture. In 2009, she joined Dr. Salmon Khetani’s team at Ascendance BioTechnology when they were in the early stages of developing micropatterned co-cultures including human, rat, monkey, mouse, and dog hepatocyte models – a system later known as HEPATOPAC. As the product was commercialized Ms. Gaffney supported all aspects of producing HEPATATOPC kits to meet growing customer demand. Ms. Gaffney continued to support production of HEPATOPAC products after BioIVT acquired the technology in 2018. At BioIVT she also provides technical assistance to our clients who are using HEPATOPAC cultures in their drug discovery and development programs.